2005 immunosuppressive strategies in kidney transplantation: Which role for the calcineurin inhibitors?

被引：40
作者：
Wong, WC
Venetz, JP
Tolkoff-Rubin, N
Pascual, M
机构：
[1] CHU Vaudois, Transplantat Ctr, CH-1011 Lausanne, Switzerland
[2] Fac Biol & Med, Lausanne, Switzerland
[3] Massachusetts Gen Hosp, Renal Unit, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Transplantat Unit, Boston, MA 02114 USA
[5] Harvard Univ, Sch Med, Boston, MA 02115 USA
来源：
TRANSPLANTATION | 2005年 / 80卷 / 03期
关键词：
calcineurin inhibitors; cyclosporine; tacrolimus; kidney transplantation; immunosuppression;
D O I：
10.1097/01.tp.0000168436.76784.45
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The calcineurin inhibitors (CNIs) cyclosporine and tacrolimus have been the cornerstones of immunosuppressive strategies in clinical transplantation. Currently, regimens that are most widely used for induction and maintenance therapy include CNIs. However, many clinical trials aiming at reducing or eliminating CNIs have been performed in recent years. Here, we review and discuss current and future immunosuppressive strategies with a special emphasis on the role of CNIs, in the light of recent studies in the field of kidney transplantation. In the current era, CNIs still play an important role.
引用
收藏
页码：289 / 296
页数：8
相关论文
共 69 条
[1]   Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study [J].
Abramowicz, D ;
Manas, D ;
Lao, M ;
Vanrenterghem, Y ;
del Castillo, D ;
Wijngaard, P ;
Fung, S .
TRANSPLANTATION, 2002, 74 (12) :1725-1734
[2]   Clinical transplantation tolerance: The promise and challenges [J].
Ansari, MJI ;
Sayegh, MH .
KIDNEY INTERNATIONAL, 2004, 65 (05) :1560-1563
[3]   Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile [J].
Artz, MA ;
Boots, JMM ;
Ligtenberg, G ;
Roodnat, JI ;
Christiaans, MHL ;
Vos, PF ;
Moons, P ;
Borm, G ;
Hilbrands, LB .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :937-945
[4]   A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients [J].
Baboolal, K .
TRANSPLANTATION, 2003, 75 (08) :1404-1408
[5]   Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients [J].
Baid-Agrawal, S ;
Delmonico, FL ;
Tolkoff-Rubin, NE ;
Farrell, M ;
Williams, WW ;
Shih, V ;
Auchincloss, H ;
Cosimi, AB ;
Pascual, M .
TRANSPLANTATION, 2004, 77 (08) :1199-1202
[6]   Diagnosis and treatment of antibody-mediated kidney allograft rejection [J].
Böhmig, G ;
Regele, H .
TRANSPLANT INTERNATIONAL, 2003, 16 (11) :773-787
[7]   LONG-TERM EFFICACY AND SAFETY OF CYCLOSPORINE IN RENAL-TRANSPLANT RECIPIENTS [J].
BURKE, JF ;
PIRSCH, JD ;
RAMOS, EL ;
SALOMON, DR ;
STABLEIN, DM ;
VANBUREN, DH ;
WEST, JC .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (06) :358-363
[8]   Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction [J].
Cai, JC ;
Terasaki, PI ;
Bloom, DD ;
Torrealba, JR ;
Friedl, A ;
Sollinger, HW ;
Knechtle, SJ .
TRANSPLANTATION, 2004, 78 (06) :919-924
[9]   Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients [J].
Calne, R ;
Moffatt, SD ;
Friend, PJ ;
Jamieson, NV ;
Bradley, JA ;
Hale, G ;
Firth, J ;
Bradley, J ;
Smith, KGC ;
Waldmann, M .
TRANSPLANTATION, 1999, 68 (10) :1613-1616
[10]  
Campistol JM, 2001, TRANSPLANTATION, V71, pSS42
1234567